NATIONAL CANCER CENTER HOSPITAL EAST
- Country
- π―π΅Japan
- Ownership
- Private
- Established
- 1962-01-01
- Employees
- -
- Market Cap
- -
Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)
- Conditions
- Anaplastic Thyroid Cancer
- Interventions
- First Posted Date
- 2023-01-25
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- National Cancer Center Hospital East
- Target Recruit Count
- 51
- Registration Number
- NCT05696548
- Locations
- π―π΅
Nippon Medical School Hospital, Tokyo, Japan
π―π΅Osaka Metropolitan University Hospital, Osaka, Japan
π―π΅Aichi Cancer Center, Nagoya, Aichi, Japan
Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)
- Conditions
- Salivary Gland Cancer
- Interventions
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- National Cancer Center Hospital East
- Target Recruit Count
- 56
- Registration Number
- NCT05694819
- Locations
- π―π΅
Hokkaido University Hospital, Sapporo, Hokkaido, Japan
π―π΅National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
π―π΅Tohoku University Hospital, Sendai, Miyagi, Japan
TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer
- Conditions
- Locally Advanced Rectal Cancer
- Interventions
- Radiation: SCRTDrug: CAPOXDrug: CAPOXIRI
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- National Cancer Center Hospital East
- Target Recruit Count
- 608
- Registration Number
- NCT05646511
- Locations
- π―π΅
Kyoto Prefectural University of Medicine, Kyoto, Japan
π―π΅Osaka Metropolitan University Hospital, Osaka, Japan
π―π΅National Cancer Center Hospital East, Chiba, Japan
Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy
- Conditions
- Gastroesophageal Junction AdenocarcinomaEsophageal AdenocarcinomaGastric Adenocarcinoma
- Interventions
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- National Cancer Center Hospital East
- Target Recruit Count
- 30
- Registration Number
- NCT05394740
- Locations
- π―π΅
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients with HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma
- Conditions
- Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- National Cancer Center Hospital East
- Target Recruit Count
- 64
- Registration Number
- NCT05034887
- Locations
- π―π΅
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib with Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients with Gastric Cancer
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- National Cancer Center Hospital East
- Target Recruit Count
- 43
- Registration Number
- NCT04745988
- Locations
- π―π΅
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
Efficacy and Safety of CRT, Durvalumab and Surgery for SST
- Conditions
- Non Small Cell Lung Cancer Stage IIISuperior Sulcus TumorNon-small Cell Lung Cancer Stage IIB
- Interventions
- First Posted Date
- 2020-07-10
- Last Posted Date
- 2020-07-10
- Lead Sponsor
- National Cancer Center Hospital East
- Target Recruit Count
- 84
- Registration Number
- NCT04465968
Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection
- Conditions
- Colorectal NeoplasmsTrifluridine and TipiracilCirculating Tumor DNA
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2022-11-18
- Lead Sponsor
- National Cancer Center Hospital East
- Target Recruit Count
- 240
- Registration Number
- NCT04457297
- Locations
- π―π΅
Hokkaido University Hospital, Sapporo, Hokkaido, Japan
π―π΅Sapporo Medical University Hospital, Sapporo, Hokkaido, Japan
π―π΅University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan
Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- National Cancer Center Hospital East
- Target Recruit Count
- 30
- Registration Number
- NCT04417192
- Locations
- π―π΅
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
π―π΅National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan
π―π΅Kurume University Hospital, Kurume, Fukuoka, Japan
Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer
- Conditions
- Rectal Cancer Recurrent
- Interventions
- Drug: ChemotherapyRadiation: Preoperative radiotherapyOther: Procedure
- First Posted Date
- 2020-02-28
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- National Cancer Center Hospital East
- Target Recruit Count
- 110
- Registration Number
- NCT04288999
- Locations
- π―π΅
Gifu University School of Medicine, Gifu, Japan
π―π΅Saitama Medical University International Medical Center, Hidaka, Japan
π―π΅Kansai Medical University Hospital, Hirakata, Japan